MetaCap

Korsana Biosciences (KRSA) vs Schrodinger (SDGR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Korsana Biosciences (KRSA) has outperformed Schrodinger (SDGR) over the past year, gaining 262.5% versus a gain of 39.2%. Over five years, SDGR leads with a -42.0% price change compared with -89.0% for KRSA. Schrodinger is the larger company by market cap ($1.72 billion vs $1.71 billion), about 1.0 times the size.

Schrodinger converts more of its revenue into profit, with a net margin of -40.4% versus -170.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KRSA+262.55%SDGR+39.22%
+349%+149%-51%
Nov 21, 20251 yearNov 20, 2026
KRSA-88.44%SDGR-43.80%
+38%-33%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KRSA versus SDGR key metrics
MetricKRSASDGR
Share price$37.56$22.93
Market cap$1.71B$1.72B
1-day change+5.95%-12.95%
YTD return+322.50%+28.24%
1-year return+262.55%+39.22%
5-year return-89.05%-42.01%
EPS (TTM)$-16.14$-0.79
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.07M$255.87M
Revenue growth (YoY)+3.70%+23.29%
Net income (latest FY)$-3.53M$-103.27M
Gross margin—55.74%
Operating margin-239.78%-65.23%
Net margin-170.11%-40.36%
52-week high$59.36$34.00
52-week low$7.19$10.95
Distance from 52-week high-36.73%-32.56%
Analyst consensusstrong_buybuy
Avg. price target upside+17.15%+46.40%
Average volume119.71K2.08M
Shares outstanding45.54M65.91M
Employees19850
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KRSA has outperformed SDGR by 223.3 percentage points over the past year.
  • Schrodinger is more profitable, keeping -40.4 cents of every revenue dollar as net income versus -170.1 cents for Korsana Biosciences.
  • Schrodinger grew revenue faster in its latest fiscal year (+23.29% vs +3.70%).

About Korsana Biosciences

KRSA stock →

Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

About Schrodinger

SDGR stock →

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.

Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees

KRSA vs SDGR FAQ

Which is bigger, Korsana Biosciences or Schrodinger?

Schrodinger (SDGR) is larger, with a market capitalization of $1.72B compared with $1.71B for Korsana Biosciences (KRSA).

Which stock has performed better over the past year, KRSA or SDGR?

KRSA returned +262.55% over the past 12 months, compared with +39.22% for SDGR (price return, excluding dividends). Past performance does not predict future results.

Are Korsana Biosciences and Schrodinger in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons